Merck Expands Industry-Leading Emprove<sup>®</sup> Program to Include Filtration and Single-Use Products
Emprove® risk assessment program provides easy access to information on materials used for drug product manufacturing
27 Jun 2016Merck, a leading science and technology company, has expanded its industry-leading Emprove® risk assessment program to include a selection of products for filtration and single-use processing.
The program provides documentation and regulatory information on materials used in the manufacture of drug products. This information enhances transparency, facilitates manufacturers' risk assessment workflows and supplier qualification.
"As the regulatory landscape continues to evolve, rapid and easy access to risk assessment information is even more critical," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. "The expansion of our Emprove® program helps ensure our customers are using only the highest quality products for their manufacturing processes."
The Emprove® program now includes Millipore Express® filters, Pureflex® and Pureflex® Plus bags, Viresolve® Pro filtration devices and Durapore® filters. The program gives customers instant access to online regulatory and technical information on a wide range of products. That information includes details on extractables, residual solvents and elemental impurities for these products. In addition, customers will find labelling information, shelf-life data and procedures, sterilization procedures, packaging testing, audit report summaries and management processes for suppliers.
Using the Emprove® program, manufacturers can download dossiers on material qualification, quality management and operational excellence in one centralized location. In the past, manufacturers had to contact multiple parties for the data. Merck's data also saves manufacturers time and money associated with their own testing.
The original Emprove® program included more than 400 raw materials and active pharmaceutical ingredients used in manufacturing drug products such as excipients, process chemicals and active pharmaceutical ingredients. The newly expanded program provides industry-leading support to customers by anticipating regulatory needs and delivering confidence that reduces risk throughout the manufacturing process.
Related Products
Request Quote for All Products
EMPROVE® exp Portfolio
MerckEMPROVE® exp for use as excipient As drug approval procedures grow stricter, regulatory requirements are becoming more demanding for excipients. Our high-quality EMPROVE® exp raw materials for use as excipients not only comply with relevant regulations, but also come with detailed documentation, facilitating lower costs of qualification, so you can get to market faster. EMPROVE® exp dossiers comprise information on the manufacturer and manufacturing process. They provide specifications in accordance with the requirements of a variety of pharmacopoeias, as well as details on impurities, stability data and a certificate of analysis (CoA). This way, we help reduce your workload and accelerate your qualification processes.EMPROVE® exp Portfolio Features: Complete Dossier (Basic, Analytical, Stability-Dossier) - Update every 12 month - CDA necessary - Charged Basic Dossier - Available online - Free of charge Analytical Dossier (Basic Dossier+Analytical Method) - CDA necessary - Charged Stability Dossier (Basic Dossier+Stability Method) - CDA necessary- Charged